Adcetris to stay leader in Hodgkin's lymphoma market, says analyst

US biotech firm Seattle Genetics (Nasdaq: SGEN) and Japanese drug major Takeda’s (TYO: 4502) Adcetris (brentuximab vedotin) to treat Hodgkin’s lymphoma will continue to lead the market in the USA and is likely to gain swift popularity following its anticipated label extension in Europe from early 2016, according to new research

Stelios Tzellos, research and consulting firm GlobalData’s analyst covering oncology and hematology, says the therapy was lauded as potentially transformational in the Hodgkin’s lymphoma treatment market at the recent 2015 American Society of Hematology (ASH) Meeting and Exposition held in Orlando, Florida.

Dr Tzellos explains: “Adcetris, a CD30-targeting agent, demonstrated a remarkable increase in progression-free survival (PFS) compared with placebo in the new post-autologous transplantation setting. Data presented at ASH indicated that the median PFS was not reached in the Adcetris-treatment arm, while it was less than 16 months in the placebo arm.